Omega Funds closed its eighth life sciences investment fund at $647 million, sustaining its commitment to backing innovative biotech companies despite broader declines in venture capital funding. The firm's portfolio includes recent successes such as acquisitions of Scorpion Therapeutics and EyeBio. Omega’s continued fundraising reflects strategic confidence in biotech innovation pipelines amid a cautious funding environment in 2025.